+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes obinutuzumab in adolescents aged 12 to less than 18 years with active Class III or IV lupus nephritis confirmed by biopsy. This phase II randomized, double-blind, placebo-controlled study also monitors the safety and pharmacokinetics of obinutuzumab in younger children aged 5 to less than 12 years with lupus nephritis. Participants aged 12 to less than 18 will be randomly assigned to receive either obinutuzumab or a placebo through intravenous infusions on Day 1, Day 14, Week 24, Week 26, and Week 52. Those weighing 45 kg or more will receive a 1000 mg dose, while those under 45 kg will receive a weight-adjusted dose. Younger participants aged 5 to less than 12 will receive open-label obinutuzumab infusions on the same schedule. All participants will also take mycophenolate mofetil orally and corticosteroids such as prednisone with dose adjustments over time. Pre-medications including acetaminophen, diphenhydramine, and methylprednisolone are given before infusions. Throughout the study, participants will undergo regular assessments including laboratory tests, kidney function evaluations, disease activity scores, and quality of life measurements up to Week 76. Researchers will monitor kidney response, adverse events, drug levels, immune responses, and other health indicators. Participants will have scheduled visits aligned with the infusion days and follow-up evaluations to track treatment effects and safety over the course of the trial, which lasts until Week 76 after the first dose.

Age: 5Years - 17YearsAll GendersPhase 2
44 locations